Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem Myeloablative Consolidation and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
NCT02605421Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2016
- Primary completion
- Oct 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, cyclophosphamide, melphalan, etoposide, carboplatin and 1 more in neuroblastoma, sponsored by Masonic Cancer Center. Primary endpoint: Progression Free Survival at 3 years. Started Jun 2016; status: recruiting.
02
Drugs
thiotepacyclophosphamidemelphalanetoposidecarboplatin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02605421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605421.